Tamás Molnár - Concepedia

Author

Tamás Molnár

Also Known As

Agota Kovacs, Agota Kovács, Harald Peeters, Helga Hajdú, Maria Beatrice Principi, Molnar, Tamas, Molnár, Tamás, Peter Bossuyt, Péter Máté, S Fox

476

Publications

6.4K

Citations

H-Index

100

Concepts

All Affiliations

University of Szeged Semmelweis University University of Debrecen University of Pecs Péterfy Sándor Utcai Kórház-Rendelőintézet és Baleseti Központ

About

Tamás Molnár is an author at University of Szeged specializing in medicine, gastroenterology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	33	2.4K
2	Public Health	6	8	285
3	Education	4	4	63
4	Health Sciences	1	1	14
5	Allergy	1	1	107

Tamás Molnár

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management Marcus Harbord, Rami Eliakim, Dominik Bettenworth, Journal of Crohn s and Colitis GastroenterologyDiagnosisCurrent ManagementClinical GastroenterologyGastrointestinal Pathology	2017	1.2K
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies Hannah Gordon, Livia Biancone, Gionata Fiorino, Journal of Crohn s and Colitis	2022	258
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort K Gecse, Barbara D. Lovász, Klaudia Farkas, Journal of Crohn s and Colitis	2015	182
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease László Kiss, Tamás Szamosi, Tamás Molnár, Alimentary Pharmacology & Therapeutics	2011	159
New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort Mária Papp, I Altorjay, Nir Dotan, The American Journal of Gastroenterology	2008	146
IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease A. Nemetz, M. P. Nosti-Escanilla, Tamás Molnár, Immunogenetics InflammationChronic Inflammatory DiseasesAutoimmune DiseaseMucosal ImmunologyGenetic Epidemiology	1999	142
A Pilot Study of Fecal Serine-Protease Activity: A Pathophysiologic Factor in Diarrhea-Predominant Irritable Bowel Syndrome R Róka, A Rosztóczy, Mathilde Lévêque, Clinical Gastroenterology and Hepatology Functional Gastrointestinal DisorderFecal Serine-protease ActivityMedicinePathogenesisGastroenterology	2007	126
Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice Anita Annaházi, K Gecse, Marta Dabek, Pain Healthy SubjectsImmunologyGastroenterologyPathologyVisceral Sensitivity	2009	107
Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota Bálint Kintses, Orsolya Méhi, Eszter Ari, Nature Microbiology Antimicrobial Resistance GeneDysbiosisHost-microbe InteractionsPhylogenetic BarriersHuman Gut Microbiota	2018	107
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center Klaudia Farkas, Mariann Rutka, Anita Bálint, Expert Opinion on Biological Therapy	2015	92

Page 1